Development and multicenter validation of a machine learning framework for predicting severe myelosuppression in nasopharyngeal carcinoma: Evidence from large-scale real-world data and prospective clinical trials.
Abstract
6023 Background: Severe treatment-related myelosuppression (Tr-MS) in nasopharyngeal carcinoma (NPC) necessitates dose reductions, compromising survival. Current static models rely on baseline "snapshots," failing to capture dynamic bone marrow fluctuations. We developed a dynamic deep learning system using longitudinal real-world data to predict cycle-specific Tr-MS risk. Methods: We analyzed 103,919 longitudinal records from 12,065 NPC patients (Nanfang/SYSUCC). A rolling-window strategy incorporated dynamic pre-dose labs, prior-cycle nadirs, and cumulative exposure to predict Grade ≥3 Tr-MS (CTCAE v6.0). Models (Logistic/XGBoost/LightGBM/TabPFN) were trained (6:3:1 split) and validated in two independent external cohorts (n=197) and three prospective trials (NCT03919552, NCT06767488, NCT06017895; n=173). The model was deployed as an EHR-integrated tool for automated real-time risk stratification. Results: Dynamic models demonstrated robust discrimination across all validation hierarchies (Table). In internal validation, AUCs ranged from 0.84 to 0.96. Performance remained stable in external cohorts (AUC 0.75-0.87) and prospective trials (AUC 0.79-0.86). SHAP analysis identified cumulative chemotherapy dosage and prior-cycle nadirs as dominant risk factors. Notably, the HIS-integrated tool successfully automated data retrieval, eliminating manual entry burden. Conclusions: This first EHR-integrated, cycle-specific dynamic system for Tr-MS in NPC captures longitudinal marrow exhaustion, enabling a shift from reactive rescue to precise, proactive prevention. Performance of dynamic prediction models across validation cohorts. Endpoint Cohort AUC (95% CI) Sens Spec Anemia Internal (n=1,231) 0.96 (0.96-0.98) 0.91 0.91 Anemia External (n=197) 0.87 (0.85-0.89) 0.89 0.86 Anemia Prospective (n=173) 0.86 (0.82-0.89) 0.88 0.86 PLT Internal (n=1,231) 0.90 (0.87-0.92) 0.79 0.84 PLT External (n=197) 0.80 (0.77-0.81) 0.81 0.82 PLT Prospective (n=173) 0.81 (0.80-0.83) 0.80 0.83 WBC/Neut Internal (n=1,231) 0.84 (0.82-0.85) 0.71 0.79 WBC/Neut External (n=197) 0.75 (0.73-0.77) 0.69 0.77 WBC/Neut Prospective (n=173) 0.79 (0.77-0.81) 0.69 0.78 Abbreviations: AUC, area under the ROC curve; PLT, thrombocytopenia; WBC/Neut, leukopenia/neutropenia; Sens, sensitivity; Spec, specificity.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (6)
Tingxi Tang
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Yutong Wang
Xiaoqing Wang
Hefei National Research Center for Physical Sciences at the Microscale and Synergetic Innovation Center of Quantum Information & Quantum Physics, New Cornerstone Science Laboratory
Ruiting Huang
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Xiangjian Zhang
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Jian Guan
Department of Environmental Science, Institute of Eco-Chongming, School of Ecological and Environmental Sciences